Thematic Investing in Tech and Media, CM Research

Cyrus Mewawalla

Thematic Investing in Tech and Media

Thematic TMT investing

CM Research

CM Research is an independent research house based in London, England. We provide global thematic research in the Technology, Media and Telecoms (TMT) sectors. 

Our focus is on disruptive technologies: how will they unfold; which industries will be impacted; and who will be the ultimate winners and losers. 

Our aim is to help investors predict share prices and corporate executives stay one step ahead of the technology trends that are shaping their industry. 

We research technology investment themes in detail and then feed the results into a scorecard system to quantify the impact of several conflicting themes on individual stocks. 

Recent themes covered include internet TV, the Internet of Things, Big Data, Mobile payments, crowdfunding, artificial intelligence, the cloud, software defined networking and Generation Hashtag.

We cover the top 500 global TMT stocks by market capitalisation and several technology start-ups and pre-IPO companies too. 

In 2015, CM Research analysts outperformed the Bloomberg Benchmark Analyst Index - which measures how good analysts are at predicting stock prices - by 7.1%.

Thematic (Sector/Industry)

Genomics as an investment theme<ul><li>Costs of sequencing a human genome have fallen to less than $1,000</li><li>China leads the world in gene sequencing</li><li>The private sector is where the most interesting MedTech companies can be found</li></ul>

Genomics as an investment themeCosts of sequencing a human genome have fallen to less than $1,000China leads the world in gene sequencingThe private sector is where the most interesting MedTech companies can be found

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

Eris Lifesciences / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/24180" target="_blank" data-smartkarma-citation="entities:24180:1">Eris Lifesciences Limited (0113824Z IN)</a> is an India-focused pharmaceutical company that produces and markets branded generic drugs. The company will be one of only a handful of listed companies that is a pure play on the Indian pharmaceutical market and the only one that is not a subsidiary of a multi-national.  Eris has filed with SEBI to list on the BSE and NSE through an offering of up to 28,875,500 secondary shares (no proceeds to the company). The bid period starts on 16 June and closes on 20 June. The price band of Rs 600-603 values the company at 34x trailing EPS, a small discount to the other pure plays. This Insight briefly discusses the business, industry, financials, and valuation.We think the valuation is reasonable; the business is attractive and would take the deal.

Eris Lifesciences Limited (0113824Z IN) is an India-focused pharmaceutical company that produces and markets branded generic drugs. The company will be one of only a handful of listed companies that is a pure play on the Indian pharmaceutical market and the only one that is not a subsidiary of a multi-national.  Eris has filed with SEBI to list on the BSE and NSE through an offering of up to 28,875,500 secondary shares (no proceeds to the company). The bid period starts on 16 June and closes on 20 June. The price band of Rs 600-603 values the company at 34x trailing EPS, a small discount to the other pure plays. This Insight briefly discusses the business, industry, financials, and valuation.We think the valuation is reasonable; the business is attractive and would take the deal. 

Eris Lifesciences: Ask Some Questions, Take the Deal

Making sense of the Global Market, Euromonitor International Ltd.

Yu Mitsuhashi

Making sense of the Global Market

Euromonitor International Ltd.

We are a global market research company focused on industries, countries, economies and consumers worldwide. Our cross-country comparable research helps your organisation identify opportunities and develop growth strategies in countries and regions across the globe. With offices around the world, 1,200 analysts in 100 countries and market research on every key trend and driver, we give you powerful access to the real story behind consumer change.

Equity Bottom-Up

As the UK is set to leave the EU, we can examine the potential impact of Brexit on retail sales of FMCG companies covered in Passport. The exact shape and form of Brexit involves many assumptions – it’s not clear at this point what deal the UK will get with the EU, or whether there will be no deal and trade will default to WTO conditions, along with the presence of other uncertainties. Euromonitor is working on the Macro Shocks model to help quantify these effects. Briefly there are three components in the model:<ol><li>Macroeconomic scenario forecasts for GDP, inflation and exchange rates from the Macro Model;</li><li>Country/category footprint of company retail sales from Competitor Analytics;</li><li>Category elasticities to income (GDP proxy) – to quantify the sensitivity of demand in relation to changes in GDP – coming from Industry Forecast Models.</li></ol>

As the UK is set to leave the EU, we can examine the potential impact of Brexit on retail sales of FMCG companies covered in Passport. The exact shape and form of Brexit involves many assumptions – it’s not clear at this point what deal the UK will get with the EU, or whether there will be no deal and trade will default to WTO conditions, along with the presence of other uncertainties. Euromonitor is working on the Macro Shocks model to help quantify these effects. Briefly there are three components in the model:Macroeconomic scenario forecasts for GDP, inflation and exchange rates from the Macro Model;Country/category footprint of company retail sales from Competitor Analytics;Category elasticities to income (GDP proxy) – to quantify the sensitivity of demand in relation to changes in GDP – coming from Industry Forecast Models.

Brexit and Its Impact on the Largest FMCG Companies

Information Technology Consultant

Ishita Jain

In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a transformation, it has attracted immense funding and attention in the past couple of years. With machines becoming intelligent, medical marvels will be like never before and plenty of medical opportunities will bloom. With the excitement afoot in the investor and research communities, this article highlights applications of machine learning that are worth observing.

In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a transformation, it has attracted immense funding and attention in the past couple of years. With machines becoming intelligent, medical marvels will be like never before and plenty of medical opportunities will bloom. With the excitement afoot in the investor and research communities, this article highlights applications of machine learning that are worth observing.

AI & Machine Learning Disrupting The Healthcare Industry

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at 2015-20 CAGR of ~12% to 434,214 in 2020.The current standard of care for newly diagnosed patients is a combination of daunorubicin and cytarabine, commonly known as 7+3. However, durable remissions occur only in a minority of adult patients. Hence r/r AML remains a disease of high unmet need, especially for “elderly” patients. Treatment landscape…

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at 2015-20 CAGR of ~12% to 434,214 in 2020.The current standard of care for newly diagnosed patients is a combination of daunorubicin and cytarabine, commonly known as 7+3. However, durable remissions occur only in a minority of adult patients. Hence r/r AML remains a disease of high unmet need, especially for “elderly” patients. Treatment landscape…

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

United Kingdom

GlaxoSmithKline PLC operates as a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GlaxoSmithKline PLC (GSK LN)

Genomics as an Investment Theme

Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...

CM Research

Eris Lifesciences: Ask Some Questions, Take the Deal

Eris Lifesciences Limited (0113824Z IN) is an India-focused pharmaceutical company that produces and markets branded generic drugs. The company...

Kemp Dolliver, CFA

Brexit and Its Impact on the Largest FMCG Companies

As the UK is set to leave the EU, we can examine the potential impact of Brexit on retail sales of FMCG companies covered in Passport. The exact...

Euromonitor International Ltd.

AI & Machine Learning Disrupting The Healthcare Industry

In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a...

Ishita Jain

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...

Dion Stéfan Büchner M.D., FCAP

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)